Latest News for: vegf
Edit
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
PR Newswire 10 Nov 2025
Edit
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at ...
Nasdaq Globe Newswire 04 Nov 2025
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity. IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors ... .
Edit
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at ...
Nasdaq Globe Newswire 04 Nov 2025
Edit
Brattleboro Reformer
20 Oct 2025
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct.
Edit
Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a ...
Nasdaq Globe Newswire 20 Oct 2025
Preclinical results support 6-month dosing, demonstrating VLTR-559’s substantially longer ocular half-life, with high drug concentrations retained in the retina compared to current anti-VEGF standard of care ... .
Edit
Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea (Santen Pharmaceutical Co Ltd)
Public Technologies 20 Oct 2025
) Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea ... VEGF ... targets vascular endothelial growth factor A (VEGF-A).
- 1